PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference
February 28, 2024 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
February 14, 2024 07:00 ET
|
PolyPid Ltd.
More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once...
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
February 12, 2024 07:00 ET
|
PolyPid Ltd.
Approximately 40 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 ...
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024
January 31, 2024 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
PolyPid Announces Private Placement for $16 Million in Gross Proceeds
January 04, 2024 16:32 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 08, 2023 07:00 ET
|
PolyPid Ltd.
Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections ...
PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors
November 07, 2023 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced...
PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023
November 01, 2023 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, Nov. 01, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
October 11, 2023 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, Oct. 11, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced...
PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023
October 09, 2023 07:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...